PRESS-RELEASE ·Filed Mar 2, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should monitor the March 9 earnings release and call for actual financial performance, LOQTORZI sales trends, and updates on clinical development. The current lack of data limits immediate trading implications.
Final — all horizons settled through T+60d
CHRS ▼ -0.61% at T+60d
NEUTRAL call ✗ call lost -0.61% · α vs SPY -9.93% · entry $1.65 → $1.64
T+1d
0.00%
call 0.00% · α +0.91%
$1.65
settled 7mo ago
T+5d
+16.97%
call +16.97% · α +18.18%
$1.93
settled 7mo ago
T+20d
-3.03%
call -3.03% · α +4.91%
$1.60
settled 6mo ago
T+60d
-0.61%
call -0.61% · α -9.93%
$1.64
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Coherus Oncology announced it will release its full-year and fourth-quarter 2025 financial results on March 9, 2026, followed by a conference call. The press release contains no actual financial data, only logistical details for the upcoming earnings announcement.
Key Facts
- Coherus Oncology will release 2025 full-year and Q4 financial results on March 9, 2026, after market close.
- Management will host a conference call at 4:30 p.m. ET on March 9 to discuss results and provide a business update.
- No financial figures or operational updates were disclosed in this announcement.
- The company uses its investor relations website for material disclosures under Regulation FD.
Financial Impact
No financial data disclosed in this release
Risk Factors
- Earnings could miss expectations given the company's small market cap ($250M) and reliance on a single commercial product.
- No forward-looking guidance is provided in this release, increasing uncertainty ahead of the report.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247524 |
11 reports for CHRS
67% Hit rate best @ T+5▲ +16.97%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Press Release | $1.34 $1.29 | ▼ −4.10% | ▼ −3.11% | $1.16 (−13.43%) |
Jul 22, 2026 10w ago | Press Release | $1.43 $1.33 | ▼ −6.99% | ▼ −9.89% | $1.16 (−18.88%) |
Jun 15, 2026 15w ago | 8-K | $1.38 $1.45 | ▲ +5.07% | ▲ +4.87% | $1.16 (−15.94%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.40 $1.54 | ▼ −10.00% | ▼ −8.22% | $1.16 (+17.14%) |
May 28, 2026 18w ago | DEFA14A | $1.65 $1.50 | ▼ −9.09% | ▼ −5.95% | $1.16 (−29.70%) |
May 11, 2026 20w ago | Press Release | $1.71 $1.36 | ▼ −20.47% | ▼ −18.74% | $1.16 (−32.16%) |
May 5, 2026 21w ago | DEFA14A | $1.75 $1.47 | ▼ −16.00% | ▼ −18.78% | $1.16 (−33.71%) |
May 4, 2026 21w ago | Press Release | $1.73 $1.57 | ▼ −9.25% | ▼ −14.89% | $1.16 (−32.95%) |
Mar 9, 2026 29w ago | Press Release | $1.95 $1.70 | ▼ −12.82% | ▼ −12.67% | $1.16 (−40.51%) |
Mar 2, 2026 30w ago | Press Release | $1.65 $1.60 | ▼ −3.03% | ▲ +4.91% | $1.16 (−29.70%) |
Showing 10 of 11
US Market Status
Market Closed — Opens Mon (64h 22m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access